See All Slides - tctmd.com

Slides

Presentation TCT 2015

Five-Year BBC ONE Outcomes

Presenter: Thierry Lefevre, Leif Thuesen, Nick Curzen

October 14, 2015

Presentation TCT 2015

Incorporating Quality-of-Life and Patient-Oriented Outcomes in the Device Regulatory Approval Process

Presenter: Andrew Farb, Gregg W. Stone, John A. Spertus

October 14, 2015

Presentation TCT 2015

Debate: Should Atheroablation Be Used More Often? No, the Present Evidence Says It Should Be Used Sparingly!

Presenter: Jeffrey W. Moses, Erick Schampaert, Gert Richardt

October 14, 2015

Presentation TCT 2015

Cerebral Embolic Protection Devices: Sentinel Dual Filter Device Update of US Pivotal Clinical Trial

Presenter: Susheel Kodali, Axel Linke

October 14, 2015

Presentation TCT 2015

Neoatherosclerosis After BRS May Occur

Presenter: Detlef G. Mathey, Nicolas M. Van Mieghem, Corrado Tamburino

October 14, 2015

Presentation TCT 2015

ADO II and Other Approaches to PDA Closure

Presenter: Ziyad M. Hijazi, Robert J. Sommer, Lars Sondergaard

October 14, 2015

Presentation TCT 2015

Gene Therapy for CHF

Presenter: Henricus J. Duckers, Bernard J. Gersh, Gary L. Schaer

October 14, 2015

Presentation TCT 2015

Key Elements of BRS Nonclinical Testing to Support IDE Approval

Presenter: Andrew Farb, Gregg W. Stone, Michael C. John

October 14, 2015

Presentation TCT 2015

Nordic III 5-Year Results: To Kiss vs Not to Kiss

Presenter: Thierry Lefevre, Leif Thuesen, Matti Jaakko Niemela

October 14, 2015

Presentation TCT 2015

The Role of TPA in the Updated Stroke Approach

Presenter: Leo Nelson Hopkins, Tudor G. Jovin, Joshua Z. Willey

October 14, 2015

Advertisement

Slides

Five-Year BBC ONE Outcomes

Incorporating Quality-of-Life and Patient-Oriented Outcomes in the Device Regulatory Approval Process

Debate: Should Atheroablation Be Used More Often? No, the Present Evidence Says It Should Be Used Sparingly!

Cerebral Embolic Protection Devices: Sentinel Dual Filter Device Update of US Pivotal Clinical Trial

Neoatherosclerosis After BRS May Occur

ADO II and Other Approaches to PDA Closure

Gene Therapy for CHF

Key Elements of BRS Nonclinical Testing to Support IDE Approval

Nordic III 5-Year Results: To Kiss vs Not to Kiss

The Role of TPA in the Updated Stroke Approach

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content